Document Detail


Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a Cancer and Leukemia Group B study.
MedLine Citation:
PMID:  2177346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Both drugs were administered to 76 eligible patients with advanced NSCLC. No patient had been previously treated with chemotherapy. Cisplatin 50 mg/m2 and carboplatin 350 mg/m2 were administered every 28 days until disease progression occurred. There was 1 complete response and the overall response rate among the 68 evaluable for response patients was 13%. Neither histological subtype nor initial performance status was a significant factor influencing response. Median survival was 5.1 months with significant differences based on initial performance status but not on histological subtype. Severe or life-threatening leukopenia and thrombocytopenia occurred in 23% and 36% of the 76 patients, respectively. There were 2 toxic deaths, 1 each due to infection and haemorrhage. The efficacy of this combination is not different from that of carboplatin alone, and the combination may be of greater benefit in patients with more responsive tumours than NSCLC.
Authors:
H Kreisman; M Goutsou; C Modeas; S L Graziano; M E Costanza; M R Green
Related Documents :
7815106 - A phase ii study of intravenous carboplatin for the treatment of recurrent gliomas.
1384136 - Carboplatin in small cell lung cancer: the royal marsden hospital experience.
12441936 - Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refr...
1649266 - Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplat...
19554376 - Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease.
20851876 - Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  26     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1990  
Date Detail:
Created Date:  1991-03-06     Completed Date:  1991-03-06     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1057-60     Citation Subset:  IM    
Affiliation:
Pulmonary Division, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*,  toxicity
Carboplatin / administration & dosage,  toxicity
Carcinoma, Non-Small-Cell Lung / drug therapy*,  mortality
Cisplatin / administration & dosage,  toxicity
Drug Evaluation
Female
Humans
Lung Neoplasms / drug therapy*,  mortality
Male
Middle Aged
Grant Support
ID/Acronym/Agency:
CA-11789/CA/NCI NIH HHS; CA-12046/CA/NCI NIH HHS; CA-16450/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepa...
Next Document:  Chemotherapy in advanced non-small cell lung cancer.